Investigational drug · Phase 3
INS018_055
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "INS018_055"
First trial start
2024
Feb 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INS018_055", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "INS018_055" as an intervention, largest first.
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
InSilico Medicine Hong Kong LimitedIndustry
NCT07687459 · 320 participants (planned) · Start Sep 9, 2026 · Primary completion Oct 30, 2029
Drug: INS018_055 tablets; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Hefei, China; Beijing, China; Fuzhou, China · 47 sites in all
- A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy SubjectsCompleted
InSilico Medicine Hong Kong LimitedIndustry
NCT05154240 · 78 participants · Start Feb 21, 2022 · Primary completion Dec 2, 2022
Drug: INS018_055; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Christchurch, New Zealand
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)Completed
InSilico Medicine Hong Kong LimitedIndustry
NCT05938920 · 71 participants · Start Jun 19, 2023 · Primary completion Aug 8, 2024
Drug: INS018_055; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Hefei, China; Beijing, China; Guangzhou, China · 22 sites in all
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary FibrosisRecruiting
InSilico Medicine Hong Kong LimitedIndustry
NCT05975983 · 40 participants (planned) · Start Feb 8, 2024 · Primary completion Feb 28, 2026
Drug: INS018_055; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Idiopathic Pulmonary Fibrosis (IPF)
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- TDI01Phase 32 trials
Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)
- AK3280Phase 31 trial
Shanghai Ark Biopharmaceutical Co., Ltd. · Idiopathic Pulmonary Fibrosis (IPF)
- HB0056Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)
- AGMB-447Phase 21 trial
Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)
- AP02Phase 21 trial
Avalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.